Who are HR's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Rifampin/isoniazid/pyrazinamide/ethambutol FDC, Rifampin, isoniazid, pyrazinamide, ethambutol, Rifampicin, Pyrazinamide, Ethambutol and Isoniazid.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hr.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

HR — Competitive Intelligence Brief

HR (HR) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-tuberculosis agent (fixed-dose combination). Area: Infectious Disease.

marketed Anti-tuberculosis agent (fixed-dose combination) Mycobacterial cell wall (isoniazid) and bacterial RNA polymerase (rifampicin) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

HR (HR) — Global Alliance for TB Drug Development. HR is a fixed-dose combination of isoniazid and rifampicin used to treat tuberculosis by inhibiting bacterial cell wall and RNA synthesis.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
HR TARGET	HR	Global Alliance for TB Drug Development	marketed	Anti-tuberculosis agent (fixed-dose combination)	Mycobacterial cell wall (isoniazid) and bacterial RNA polymerase (rifampicin)
Rifampin/isoniazid/pyrazinamide/ethambutol FDC	Rifampin/isoniazid/pyrazinamide/ethambutol FDC	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Anti-tuberculosis agent (fixed-dose combination)	Bacterial RNA polymerase (rifampin), mycolic acid synthesis (isoniazid), membrane potential/energy metabolism (pyrazinamide), arabinosyl transferase (ethambutol)
Rifampin, isoniazid, pyrazinamide, ethambutol	Rifampin, isoniazid, pyrazinamide, ethambutol	ANRS, Emerging Infectious Diseases	marketed	Anti-tuberculosis agent (fixed-dose combination)	Multiple: RNA polymerase (rifampin), mycolic acid synthesis (isoniazid), arabinosyl transferases (ethambutol), pyrazinamidase/nicotinamidase (pyrazinamide)
Rifampicin, Pyrazinamide, Ethambutol and Isoniazid	Rifampicin, Pyrazinamide, Ethambutol and Isoniazid	University of Cape Town	phase 3	Anti-tuberculosis agent (fixed-dose combination)	Bacterial RNA polymerase (rifampicin), mycolic acid synthesis (isoniazid), cellular metabolism (pyrazinamide), arabinosyl transferase (ethambutol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anti-tuberculosis agent (fixed-dose combination) class)

ANRS, Emerging Infectious Diseases · 1 drug in this class
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 1 drug in this class
Global Alliance for TB Drug Development · 1 drug in this class
University of Cape Town · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HR — Competitive Intelligence Brief. https://druglandscape.com/ci/hr. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab